Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19. (August 2021)

• Record Type: Journal Article
• Authors: Kocayiğit, Havva; Demir, Gürkan; Karacan, Alper; Süner, Kezban Özmen; Tomak, Yakup; Yaylacı, Selçuk; Dheir, Hamad; Kalpakci, Yasin; Erdem, Ali Fuat
• Is Part Of: Transfusion and apheresis science. Volume 60:Number 4(2021)
• Publication Date: 2021-08
• Subjects: COVİD-19 -- Intensive care -- Convalescent plasma; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2021.103148
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first seen in the city of Wuhan, China, in December 2019 and then spread worldwide. On 24 March 2020, the U.S. Food and Drug Administration reported that the use of convalescent plasma (CP) containing antibodies against COVID-19 could be effective against infection. The aim of this study is to retrospectively investigate whether early CP transfusion treatment has an effect on recovery of clinical and laboratory parameters in patients diagnosed with severe COVID-19 who were admitted to the intensive care unit (ICU). The study included 141 consecutive patients who had laboratory confirmation of COVID-19 and were admitted to the ICU between 1 May and 30 September 2020. Of the 141 patients, 84 received CP in the first five days of hospitalization in the ICU (early group), and 57 received CP after the fifth day of hospitalization in the ICU (late group). There were no significant differences between the two groups in terms of age, gender, comorbidities and the severity of the disease (according to the evaluation of lung tomography). There was no difference between the two groups in terms of mechanical ventilator needed, inotrope support, and tracheostomy procedure during the ICU admission (p = 0.962, p = 0.680, and p = 0.927, respectively). Despite these limitations, the overriding result of our study is that it suggests that administration of CP either early or late in the treatment of COVID-19, had no effect on mortality.